Latest Updates
|
Second Quarter 2010 New Drug Updates and
Additions
|
Designation
|
Brand Name
|
Generic Name
|
|
AMEP |
|
|
Aplidin R (Aplidine) |
Plitidepsin, dehydrodidemnin B |
|
ATT (Apoptosis Targeted Therapy) |
|
|
BiovaxID |
|
|
Doxorubicin (Doxorubicine) Transdrug |
Doxorubicin |
|
Reolysin (formerly Reosyn) |
|
|
SB1518, ONX0803 |
|
|
Silybin |
Silibinin |
|
StemEX |
Carlecortemcel-l |
124-Iodine-cG250 (124I-cG250), CAN9-SCAN, WX/20-001 |
Redectane |
|
ABR-215050 |
TASQ |
Tasquinimod |
ABT-263, RG7423 |
|
Navitoclax |
ABT-888, NSC 737664 |
|
Veliparib |
Actinium-225-HuM195, HuM195-Ac-225 |
|
|
ADI-PEG, ADI-PEG-20, ADI-PEG-SS 20,000 mw |
|
|
ADXS11-001, Lm-LLO-E7 |
Lovaxin C |
|
AG-003, AGS-003 |
Arcelis |
|
ALS-357 |
|
Betulinic acid |
AMG-386, AMG386, AMG 386 |
|
|
AMG706, AMG-706 |
|
Motesanib diphosphate |
AN-152, AN 152, ZEN-008, AEZS-108 |
|
Doxorubicin |
Anti-PlGF, TB-403, TH403, RG7334 |
|
|
ANX-510 |
CoFactor |
Fotrexorin |
ANX-530, formerly SDP-012 |
Exelbine |
Vinorelbine tartrate |
AP23573, MK-8669 |
|
Ridaforolimus (formerly deforolimus) |
AP5346 |
ProLindac |
|
APC8024, BA7072 |
Neuvenge |
Lapuleucel-T |
Aplidin R (Aplidine) |
|
Plitidepsin, dehydrodidemnin B |
AR119, RDEA119 |
|
|
ARQ-650RP, ARQ 650RP, ARQ 197, ARQ197 |
|
|
ARRY-334543, ARRY-543 |
|
|
ARRY-380, ARRY-333786 |
|
|
ARRY-520 |
|
|
ARRY-614 |
|
|
ARRY-704, AZD8330 |
|
|
ART010 |
|
|
AS1413, NSC 308847 |
Formerly Xanafide |
Amonafide L-malate |
Atu027/Atu093 |
|
|
AV-299, SCH900105 |
|
|
AV-951, formerly KRN951 |
|
Tivozanib |
AVL-292 |
|
|
AZD2171, AZD 2171, NSC-732208 |
Recentin |
Cediranib |
AZD6244, ARRY-142886, ARRY-886 |
|
|
BAY 57-9352 |
|
Telatinib |
BIIB022 |
|
|
BKT-140 |
|
|
BLX-301 |
|
|
BMN-673, LT-673 |
|
|
BMS-582664 |
|
Brivanib alalinate |
BMS-754807 |
|
|
BP-100-1.01, L-Grb2, Grb-2 |
|
|
CAL-101 |
|
|
CAP-232, TT-232, TLN-232 |
|
|
carbonic anhydrase (CA) IX (CA9 or MN) antigen vaccine |
|
|
carcinoembryonic antigen (CEA) vaccine |
|
|
CDX-110, ALT-110, PF-4948568 |
|
|
CDX-1127 |
|
|
CGC-11047, PG-11047, SL-11047 |
|
|
CGC-11093 |
|
|
CGC-11102, CGC-11157, CGC-11217, CGC-11294 |
|
|
CP-4055 |
Elacyt |
Ara-C, elacytarabine |
CP-4126, CO-1.01 |
|
Gemcitabine 5'-elaidic acid ester |
CP-4200 |
|
5-Azacitidine (AzaC) |
CP-751871, CP-751,871 |
|
Figitumumab |
CRS-207 |
|
|
CS7017, CS-7017 |
|
|
CUDC-101 |
|
|
Cur-691, GDC-0449, RG3616 |
HhAntag |
|
CYT387 |
|
|
D-24851, ZIO-301 |
Zybulin |
Indibulin |
D3263, D-3263 |
|
|
DOX-LTSL |
ThermoDox |
Doxorubicin |
DPX-0907 |
|
|
E7389, NSC-707389 (formerly ER-086526) |
|
Eribulin mesylate |
EG009, ad.HSV tk |
Cerepro |
|
EG01257 |
|
|
ENMD-981693, ENMD-2076 |
|
|
EPO906 |
Patupilone |
|
F50035, MK-0646, MK0646 |
|
Dalotuzumab |
GA101, RO5072759, RG7159 |
GlycoMAb |
|
GAP-107B8 , PhGalpha1, PhGalpha-1 |
|
|
GDC-0152 |
|
|
GVAX leukemia vaccine, GM-K562, GVAX CML |
|
|
GVAX prostate cancer vaccine, CG1940/CG8711 |
|
|
HKI-272 |
|
Neratinib |
HKI-357 |
|
|
HuM195/rGel |
|
|
HuMax-CD38 |
|
|
HYB2055, IMO-2055, EMD 1201081 |
IMOxine |
|
ICT-107 |
|
|
IMC-A12, NSC-742460 |
|
Cixutumumab |
IMMU-103, hLL2, hCD22, AMG 412 |
LymphoCide |
Epratuzumab |
IMMU-106, hA20, hCD20 |
|
Veltuzumab |
INSM-18 |
|
|
IPP-204106, Nucant 6L |
|
|
IRX-2 |
|
Citoplurikin |
JX-594 |
|
|
KRX-0401, D-21266 |
|
Perifosine |
L-BLP25, BLP-25 (formerly BP1-7-KLH) |
Stimuvax |
|
LBH 589, LBH589, NVP-LBH589, LBH489B, LBH489A |
|
Panobinostat |
LEP-ETU (formerly PNU-93914) |
|
Paclitaxel |
Liposome Entrapped Docetaxel for Injection (LE-DT) |
|
Docetaxel |
LOR-253, ML-220, ML-series (ML-133 and LT-253) |
|
|
MDX-010, MDX-CTLA4; BMS-734016 |
|
Ipilimumab |
MDX-1307, HCG-VAC, CDX-1307 |
|
|
MEDI-573 |
|
|
MGCD0103 |
|
Mocetinostat |
MGCD265 |
|
|
MGN1601 |
|
|
MKC1106-PP, MKC-1106 |
|
|
MOR 202, MOR202 |
|
|
NBI-56418 |
|
Elagolix |
NPC-1C |
|
Ensituximab |
NPI-2350 and NPI-2358 |
|
|
NS-187, INNO-406, CNS-9 |
|
Bafetinib |
NSC-649890, L86-8275, HMR-1275, HMR1275 |
|
Alvocidib, flavopiridol |
OMP-18R5 and others |
|
|
OMP-21M18 |
|
|
ON 013105 |
|
|
ON 01910.Na, ON01910.Na, ON01910 |
Estybon |
|
ON 24160 |
|
|
OncoVEX GM-CSF, OncoVEXGMCSF |
|
|
OSI-906 |
|
|
OSU-03012, AR-12 |
|
|
OSU-HDAC42, s-HDAC-42, NSC D736012, AR-42 |
|
|
PF-2341066, PF-2,341,066, PF-02341066, PF1066, PF-1066 |
|
Crizotinib |
PF-3446962, PF-3,446,962, PF-03446962 |
|
|
PI-88 |
|
Muparfostat |
PM-10450, PM00104 |
Zalypsis |
|
PRO70769, R1594 |
|
Ocrelizumab |
PTC-210 |
|
|
PTC299 |
|
|
PX-478 |
|
|
PX-866, PX866 |
|
|
R1507, RG1507, formerly Roche 1 |
|
|
SAR3419 |
|
|
SAR650984 |
|
|
SCH 717454 |
|
|
Series PG500, PG545 |
|
|
SGN-35, SGN35 |
|
Brentuximab vedotin |
SKI-606 |
|
Bosutinib |
SL-052, SL052 |
|
Hypocrellin B |
SL-052, SL052 |
|
Hypocrellin B |
SNS-595, SPC-595 (formerly AG-7352) |
|
Voreloxin |
SOM230, SOM230C |
|
Pasireotide |
Specifid, formerly FavId |
|
Imitumprotimut-T |
SRT501 |
|
|
STA-9090 |
|
|
Sym004 |
|
|
VEGF Trap, VEGF-Trap, AVE0005, NSC 724770 |
|
Aflibercept |
VGX-3100 |
|
|
WX-G250, anti-G250, cG250 |
Rencarex |
|
XL184, XL 184, EXEL-7184, BMS 907351 |
|
|
XL765 |
|
|
XL880, XL-880, GSK1363089, GSK089 |
|
Foretinib |
XMT-1001, MER-1001 |
|
|
ZD6474, AZD6474, AZD-6474 |
Zactima |
Vandetanib |
ZK-BA, 131-I-MIP-1145 |
Solazed |
Ioflubenzamide I-131 |
[18F]-ML-10 |
ApoSense |
|
|
NEW MEDICINE, INC.
P.O. BOX 909, LAKE FOREST, CA 92609
PHONE: 1-949-830-0448 FAX: 1-949-830-0887
INFO@NEWMEDINC.COM
|